Global Biologics Market Insights As Per TBRC’s Latest Report
The biologics market size was worth more than $200 billion in 2017 and is essentially segmented into monoclonal antibodies, therapeutic proteins and vaccines.
(EMAILWIRE.COM, December 31, 2018 ) The global biologics market comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, vaccines, and monoclonal antibodies. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.
Order Report at https://www.thebusinessresearchcompany.com/report/biologics-global-market-opportunities-and-strategies-to-2021
Biologics Market Segmentation
The biologics market size was worth more than $200 billion in 2017 and is essentially segmented into monoclonal antibodies, therapeutic proteins and vaccines.
Monoclonal Antibodies are cells derived by cell division from a single ancestral cell. Monoclonal antibodies target specific cell-surface receptors. These mAbs recognize and bind to antigens, a molecule that induces the immune system, in order to discriminate between specific epitopes (the part of an antigen that is recognized by the antibody) which provide protection against disease organisms. The monoclonal antibodies market was the largest segment in the biologics market accounting for more than $90 billion or 40% of the market. This was due to the high prevalence of diseases such as rheumatoid arthritis, Crohn’s disease and ulcerative colitis for which monoclonal antibodies are used.
Download sample report for free at https://www.thebusinessresearchcompany.com/sample.aspx?id=792&type=smp
Despite being the second largest market, vaccines had the highest CAGR (compound annual growth rate) of around 6% during 2013-2017; this segment is expected to grow at a CAGR of more than 9% during 2017-2021. The rapid growth in this market can be attributed to the increasing government and non-government initiatives for vaccine R&D activities and prevention of various infectious diseases. Various bivalent and pentavalent vaccines that can prevent an individual from more than one disease have also been developed and are being administered in many countries across the world.
Top biologics companies which engage in biologics manufacturing included in the report are Johnson & Johnson, F.Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, and AbbVie.
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company
Order Report at https://www.thebusinessresearchcompany.com/report/biologics-global-market-opportunities-and-strategies-to-2021
Biologics Market Segmentation
The biologics market size was worth more than $200 billion in 2017 and is essentially segmented into monoclonal antibodies, therapeutic proteins and vaccines.
Monoclonal Antibodies are cells derived by cell division from a single ancestral cell. Monoclonal antibodies target specific cell-surface receptors. These mAbs recognize and bind to antigens, a molecule that induces the immune system, in order to discriminate between specific epitopes (the part of an antigen that is recognized by the antibody) which provide protection against disease organisms. The monoclonal antibodies market was the largest segment in the biologics market accounting for more than $90 billion or 40% of the market. This was due to the high prevalence of diseases such as rheumatoid arthritis, Crohn’s disease and ulcerative colitis for which monoclonal antibodies are used.
Download sample report for free at https://www.thebusinessresearchcompany.com/sample.aspx?id=792&type=smp
Despite being the second largest market, vaccines had the highest CAGR (compound annual growth rate) of around 6% during 2013-2017; this segment is expected to grow at a CAGR of more than 9% during 2017-2021. The rapid growth in this market can be attributed to the increasing government and non-government initiatives for vaccine R&D activities and prevention of various infectious diseases. Various bivalent and pentavalent vaccines that can prevent an individual from more than one disease have also been developed and are being administered in many countries across the world.
Top biologics companies which engage in biologics manufacturing included in the report are Johnson & Johnson, F.Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, and AbbVie.
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company
Contact Information:
The Business Research Company
Marketing TBRC
Tel: +91 8897263534
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Business Research Company
Marketing TBRC
Tel: +91 8897263534
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results